WINSTON-SALEM – Javara, a clinical research services firm that is actively involved in the fight against the COVID-19 pandemic with multiple partners, has raised $4.6 million in new capital.

Eleven investors are backing Javara, according to a securities filing.

The new cash follows a funder that produced $3.775 million in August of last year.

Javara earlier this month announced its partnership with Wake Forest Baptist Health to begin recruiting patients for a COVID-19 vaccine trial.

More about Javara

Javara CEO aims to improve patient participation in clinical trials